Reagan Jarvis
Chief Executive Officer Anocca
Dr. Reagan Jarvis is the Co-Founder and Chief Executive Officer of Anocca AB, where he leads the development of innovative TCR-based therapies. With over a decade of experience at Anocca, Reagan has overseen the company’s transition from early research to advanced therapeutic development.
He began his postdoctoral research at the DKFZ German Cancer Research Center and previously served as a Research Fellow at the University of Otago. Reagan earned his Ph.D. in Biochemistry from the University of Otago, where he also completed his BSc (Hons) in Biochemistry
Seminars
Wednesday 25th February 2026
Panel Discussion: Leveraging AI & Machine Learning to Accelerate R&D & Construct Design
2:40 pm
- Explore how AI-driven tools are being applied to design next- generation receptor constructs with improved precision and functionality
- Discuss the use of machine learning in identifying novel targets and accelerating preclinical discovery
- Highlight the challenges of obtaining sufficient, high-quality datasets
Thursday 26th February 2026
Non-Viral Gene-Edited Manufacturing to Advance TCR-T Therapies
2:30 pm
- Non-viral gene-edited TCR gene integration for potent TCR-T cell therapies
- Scalable manufacturing inputs to support scale-out and reduce timelines to FIH products
- Enable scalable, cost-effective TCR-T therapy delivery to meet growing clinical demand
Thursday 26th February 2026
Integrating TCR-T Therapies into Existing Standard of Care
9:15 am
- Outline a unique clinical trial design aimed at embedding TCR-T therapies within existing oncology treatment pathways
- Discuss how focused umbrella trial designs accelerate development of TCR-T product libraries
